Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 9.2%

Gain Therapeutics, Inc. (NASDAQ:GANX) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 718,700 shares, a growth of 9.2% from the October 31st total of 658,300 shares. Approximately 2.9% of the company’s stock are short sold. Based on an average daily volume of 385,200 shares, the days-to-cover ratio is currently 1.9 days.

Gain Therapeutics Stock Performance

Gain Therapeutics stock opened at $1.59 on Wednesday. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $5.33. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The business’s 50-day simple moving average is $2.10 and its two-hundred day simple moving average is $1.69.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on GANX. Chardan Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, November 25th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, August 14th.

Hedge Funds Weigh In On Gain Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Warberg Asset Management LLC acquired a new stake in shares of Gain Therapeutics during the 2nd quarter worth approximately $66,000. Renaissance Technologies LLC grew its position in Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares during the period. Geode Capital Management LLC increased its holdings in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares in the last quarter. Finally, Hohimer Wealth Management LLC acquired a new position in shares of Gain Therapeutics in the second quarter worth about $422,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.